SEHK:1913
SEHK:1913Luxury

Asian Dividend Stocks To Consider For Your Portfolio

As global markets navigate a landscape marked by U.S.-China trade tensions and monetary policy shifts, investors are increasingly looking toward Asia for opportunities in dividend stocks. In such a dynamic environment, a good dividend stock is typically characterized by its ability to maintain stable payouts and demonstrate resilience amid economic fluctuations.
SEHK:1929
SEHK:1929Specialty Retail

3 Asian Dividend Stocks Offering Yields Up To 6.4%

As global markets navigate a period of volatility marked by trade tensions and monetary policy shifts, investors are increasingly turning their attention to Asia for opportunities. In this context, dividend stocks can offer a compelling option for those seeking income stability amid economic uncertainties.
SEHK:2171
SEHK:2171Biotechs

High Growth Tech Stocks in Asia to Watch

As the Asian tech sector navigates a landscape marked by evolving U.S.-China trade dynamics and ongoing economic adjustments, investors are keenly observing how these factors impact growth trajectories. In such an environment, identifying high-growth tech stocks involves assessing companies that demonstrate resilience through innovation and adaptability in response to shifting market conditions.
SEHK:1177
SEHK:1177Pharmaceuticals

Does Sino Biopharm Offer Value After Jumping 135% and Expanding in Asia in 2025?

If you have been watching Sino Biopharmaceutical, you are probably wondering what to make of this stock after such a rollercoaster ride. The past year has brought a surge that few predicted, with the stock up an eye-catching 135.6% since the start of the year and 95.3% over the last twelve months. Even looking back three years, the company has notched an impressive 83.5% gain. Yet, this momentum hit a speed bump recently, with prices dropping 6.7% in the last week and falling 13.2% over the...
SEHK:1357
SEHK:1357Interactive Media and Services

Meitu (SEHK:1357): Assessing Valuation After Recent 5% Share Price Dip

Meitu (SEHK:1357) shares have seen a dip, with the stock slipping over 5% in recent trading. Investors are watching closely as the company navigates shifting market sentiment and re-evaluates its business strategies. See our latest analysis for Meitu. Meitu's recent slide comes after a year marked by dramatic momentum shifts, with the share price posting an impressive year-to-date return of 185.76%. Short-term volatility aside, long-term investors have enjoyed a stellar one-year total...
SEHK:2096
SEHK:2096Pharmaceuticals

Evaluating Simcere Pharmaceutical Group (SEHK:2096) Valuation After First U.S. Patient Dosed in Oncology Trial

Simcere Pharmaceutical Group (SEHK:2096) has advanced its oncology program with the first U.S. patient dosed in the Phase 1 trial of SIM0505 for advanced solid tumors. This development expands the clinical reach beyond China and draws investor attention to ongoing trial progress. See our latest analysis for Simcere Pharmaceutical Group. Simcere’s recent momentum is hard to miss, with the stock’s 91.5% year-to-date share price return fueled by progress in its expanding oncology pipeline...